Loughney Lisa, West Malcolm A, Kemp Graham J, Rossiter Harry B, Burke Shaunna M, Cox Trevor, Barben Christopher P, Mythen Michael G, Calverley Peter, Palmer Daniel H, Grocott Michael P W, Jack Sandy
Anaesthesia and Critical Care Research Area, NIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, CE93, MP24, Tremona Road, Southampton, SO16 6YD, UK.
Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, CE93, MP24, Tremona Road, Southampton, SO16 6YD, UK.
Trials. 2016 Jan 13;17:24. doi: 10.1186/s13063-015-1149-4.
The standard treatment pathway for locally advanced rectal cancer is neoadjuvant chemoradiotherapy (CRT) followed by surgery. Neoadjuvant CRT has been shown to decrease physical fitness, and this decrease is associated with increased post-operative morbidity. Exercise training can stimulate skeletal muscle adaptations such as increased mitochondrial content and improved oxygen uptake capacity, both of which are contributors to physical fitness. The aims of the EMPOWER trial are to assess the effects of neoadjuvant CRT and an in-hospital exercise training programme on physical fitness, health-related quality of life (HRQoL), and physical activity levels, as well as post-operative morbidity and cancer staging.
METHODS/DESIGN: The EMPOWER Trial is a randomised controlled trial with a planned recruitment of 46 patients with locally advanced rectal cancer and who are undergoing neoadjuvant CRT and surgery. Following completion of the neoadjuvant CRT (week 0) prior to surgery, patients are randomised to an in-hospital exercise training programme (aerobic interval training for 6 to 9 weeks) or a usual care control group (usual care and no formal exercise training). The primary endpoint is oxygen uptake at lactate threshold ([Formula: see text] at [Formula: see text]) measured using cardiopulmonary exercise testing assessed over several time points throughout the study. Secondary endpoints include HRQoL, assessed using semi-structured interviews and questionnaires, and physical activity levels assessed using activity monitors. Exploratory endpoints include post-operative morbidity, assessed using the Post-Operative Morbidity Survey (POMS), and cancer staging, assessed by using magnetic resonance tumour regression grading.
The EMPOWER trial is the first randomised controlled trial comparing an in-hospital exercise training group with a usual care control group in patients with locally advanced rectal cancer. This trial will allow us to determine whether exercise training following neoadjuvant CRT can improve physical fitness and activity levels, as well as other important clinical outcome measures such as HRQoL and post-operative morbidity. These results will aid the design of a large, multi-centre trial to determine whether an increase in physical fitness improves clinically relevant post-operative outcomes.
ClinicalTrials.gov NCT01914068 (received: 7 June 2013).
University Hospital Southampton NHS Foundation Trust.
局部晚期直肠癌的标准治疗途径是新辅助放化疗(CRT)后进行手术。新辅助CRT已被证明会降低体能,而这种降低与术后发病率增加有关。运动训练可以刺激骨骼肌适应性变化,如增加线粒体含量和改善摄氧能力,这两者都是体能的影响因素。EMPOWER试验的目的是评估新辅助CRT和院内运动训练计划对体能、健康相关生活质量(HRQoL)、身体活动水平以及术后发病率和癌症分期的影响。
方法/设计:EMPOWER试验是一项随机对照试验,计划招募46例局部晚期直肠癌患者,这些患者正在接受新辅助CRT和手术。在术前完成新辅助CRT(第0周)后,患者被随机分配到院内运动训练计划组(进行6至9周的有氧间歇训练)或常规护理对照组(常规护理且无正式运动训练)。主要终点是通过在整个研究的多个时间点进行心肺运动测试测量的乳酸阈时的摄氧量([公式:见正文]时的[公式:见正文])。次要终点包括使用半结构化访谈和问卷评估的HRQoL,以及使用活动监测器评估的身体活动水平。探索性终点包括使用术后发病率调查(POMS)评估的术后发病率,以及使用磁共振肿瘤退缩分级评估的癌症分期。
EMPOWER试验是第一项比较局部晚期直肠癌患者的院内运动训练组和常规护理对照组的随机对照试验。该试验将使我们能够确定新辅助CRT后的运动训练是否可以改善体能和活动水平,以及其他重要的临床结局指标,如HRQoL和术后发病率。这些结果将有助于设计一项大型多中心试验,以确定体能的提高是否能改善临床相关的术后结局。
ClinicalTrials.gov NCT01914068(收到日期:2013年6月7日)。
南安普敦大学医院国民保健服务基金会信托基金。